A US gunman blaming the COVID-19 vaccine for his depression fatally shot a CDC officer, highlighting the deadly consequences ...

Ministers are preparing to boost NHS spending on US drugs in a race to avoid a future tariff hit from Donald Trump.

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

Former Gov. Andrew M. Cuomo acknowledged that he had not run an effective race in the mayoral primary and asked for ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.